Baseline characteristics of the double blind treatment groups
| Variable | Dalteparin (n=1049) | Placebo (n=1056) |
|---|---|---|
| *Blood samples for central troponin T analysis were obtained at randomisation in 999 and 1015 patients, respectively. | ||
| †Determined echocardiographically in 842 and 860 patients, respectively. | ||
| CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty. | ||
| Age (years), median (range) | 67 (37–91) | 67 (38–87) |
| Male/female (%) | 68/32 | 69/31 |
| Coronary risk factors | ||
| Hypertension | 33% | 33% |
| Cholesterol >5.5 mmol/l | 53% | 57% |
| Current smoker | 25% | 27% |
| Diabetes mellitus | 14% | 12% |
| Previous and current cardiac disease | ||
| Previous MI | 30% | 27% |
| Previous PTCA | 4% | 4% |
| Previous CABG | 14% | 13% |
| Angina >48 h | 70% | 70% |
| Chest pain at rest | 82% | 80% |
| ST depression at entry | 46% | 50% |
| Troponin T ≥0.1 μg/l* | 57% | 60% |
| LVEF <45%† | 14% | 17% |